Trial Profile
Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Registry for Patients Treated With Strimvelis (or GSK2696273) Gene Therapy: Long-Term Prospective, Non-Interventional Follow-up of Safety and Effectiveness
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs GSK 2696273 (Primary)
- Indications Adenosine deaminase deficiency
- Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- Sponsors Fondazione Telethon; GlaxoSmithKline; GSK; Orchard Therapeutics
- 29 Mar 2018 New trial record